April 15, 2025
admin
Biocon subsidiary secured entry for Yesafili in USA
(20 second reading) Biocon share price jumped over 4% on Tuesday after the company announced that its subsidiary has secured market entry date for Yesafili, an interchangeable biosimilar to Eylea, in the US. Biocon shares spiked as much as 4.06% to ₹329.40 apiece on the BSE.
Biocon Biologics Ltd, a subsidiary of Biocon, announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States.
Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, and is a biosimilar of its reference product EYLEA (aflibercept).
Quicklinks
